Milestone Pharmaceuticals Inc. (MIST) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Montreal, QC, 캐나다. 현재 CEO는 Joseph G. Oliveto.
MIST 을(를) 보유 IPO 날짜 2019-05-09, 33 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $174.35M.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
